Scope of the Report The report titled “Global Regenerative Medicine Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)”, provides an in-depth analysis of the global regenerative medicine market with description of market sizing and growth. The analysis includes market by value, by product, by material and by region. Furthermore, the report also provides detailed product analysis, material analysis and regional analysis.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global regenerative medicine market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Some of the major players operating in the global regenerative medicine market are Novartis AG, Medtronic Plc, Bristol Myers Squibb (Celgene Corporation) and Smith+Nephew (Osiris Therapeutics, Inc.), whose company profiling has been done in the report. Furthermore, in this segment of the report, business overview, financial overview and business strategies of the respective companies are also provided.
North America Europe Asia Pacific ROW
Company Coverage Novartis AG Medtronic Plc Bristol Myers Squibb (Celgene Corporation) Smith+Nephew (Osiris Therapeutics, Inc.)
Executive Summary Regenerative medicines emphasis on regeneration or replacement of tissues, cells or organs of human body to cure the problem caused by disease or injury. The treatment fortify human cell’s to heal up or transplant stem cells into the body to regenerate lost tissues or organs or to recover impaired functionality. There are three types of stem cells that can be used in regenerative medicine: somatic stem cells, embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).
The regenerative medicine also has the capability to treat chronic diseases and conditions, including Alzheimer’s, diabetes, Parkinson’s, heart disease, osteoporosis, renal failure, spinal cord injuries, etc. Regenerative medicines can be bifurcated into different product type i.e., cell therapy, tissue engineering, gene therapy and small molecules and biologics. In addition, on the basis of material regenerative medicine can be segmented into biologically derived material, synthetic material, genetically engineered materials and pharmaceuticals.
The global regenerative medicine market has surged at a progressive rate over the years and the market is further anticipated to augment during the forecasted years 2020 to 2024. The market would propel owing to numerous growth drivers like growth in geriatric population, rising global healthcare expenditure, increasing diabetic population, escalating number of cancer patients, rising prevalence of cardiovascular disease and surging obese population.
Though, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: legal obligation and high cost of treatment. Whereas, the market growth would be further supported by various market trends like three dimensional bioprinting , artificial intelligence to advance regenerative medicine, etc.
Our reports have been used by over 10K customers, including:
Regenerative Medicine Market Value forecast, New Business Opportunities and Companies: Outlook By Type, Application, By End User and By Country, 2020- 2026 The study predicts the short term and long term trends that can shape up the future of the Regenerative Medicine market including the COVID-19 pandemic implications...
Alpha L-Iduronidase - Pipeline Review, H2 2020 Summary Alpha L-Iduronidase (IDUA or EC 126.96.36.199) - Alpha L-iduronidase is an enzyme encoded by IDUA gene. It hydrolyzes the terminal alpha-L-iduronic acid residues of two glycosaminoglycans, dermatan sulfate and heparan sulfate. Mutations in this gene...
INTRODUCTION Over the years, advances in cell biology and pharmacology have led to the development of a variety of advanced biologics, which experts believe, possess the potential to address several unmet needs associated with the treatment of different types of diseases. Currently, there are more than 1,000 cell and gene...
219 pages •
By Asia Market Information & Development Company
• Sep 2020
China’s demand for Monoclonal Antibody has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...
Transforming Growth Factor Beta 1 - Pipeline Review, H2 2020 Summary Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-?1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.